Cargando…

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders

INTRODUCTION: Maintaining remission, preventing from future episodes, better treatment adherence and improving the quality of life are main aims of long-term treatment in bipolar disorders (BD). In recent years, new generation long-acting injectable (LAI) antipsychotics have been frequently used in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yavuz, E., Altınbaş, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661534/
http://dx.doi.org/10.1192/j.eurpsy.2023.1457
_version_ 1785137998491287552
author Yavuz, E.
Altınbaş, K.
author_facet Yavuz, E.
Altınbaş, K.
author_sort Yavuz, E.
collection PubMed
description INTRODUCTION: Maintaining remission, preventing from future episodes, better treatment adherence and improving the quality of life are main aims of long-term treatment in bipolar disorders (BD). In recent years, new generation long-acting injectable (LAI) antipsychotics have been frequently used in maintenance treatment for bipolar disorders. OBJECTIVES: We aimed to review socio-demographic and clinical characteristics of bipolar patients taking LAI treatment for maintenance treatment. METHODS: Clinical records of 56 bipolar patients who are on LAI treatment and followed in Mazhar Osman Mood Clinic (MOMC) of Selcuk University Medical Faculty were evaluated. Descriptive statistical analysis was performed with Statistical Package for the Social Sciences (SPSS). RESULTS: Nearly half of the patients were male (n:29, 52%). 49,1% of the patients were married. The mean age was 37.1±12.2 years and the mean duration of education was 11.1±4.2 years. All of the patients were diagnosed with bipolar 1 disorder. Most of the patients (64,7%) was on aripiprazole LAI while remaining was receiving paliperidone LAI for maintenance treatment. We found a significant reduction in the number of manic episodes after long-acting treatment (p<0.001), but we could not find any difference for depression. Ten of the patients discontinued the treatment due to the side effects, extrapyramidal side effects were the most common side effects. Eight of the patients were switched from paliperidone treatment to aripiprazole treatment due to side effects, especially hyperprolactinemia. Relapse was observed in 46,4% of the patients and there was no difference between aripiprazole and paliperidone in terms of relapse rate. CONCLUSIONS: LAI new generation antipsychotics are taking place in long-term treatment of bipolar disorder via improving treatment adherence. Side effect profile of aripiprazole and paliperidone are different. However, we could not find any difference between two drugs in terms of side effects and relapse rates. Small sample size and shorter duration of follow-up should be considered as limitations. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10661534
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-106615342023-07-19 Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders Yavuz, E. Altınbaş, K. Eur Psychiatry Abstract INTRODUCTION: Maintaining remission, preventing from future episodes, better treatment adherence and improving the quality of life are main aims of long-term treatment in bipolar disorders (BD). In recent years, new generation long-acting injectable (LAI) antipsychotics have been frequently used in maintenance treatment for bipolar disorders. OBJECTIVES: We aimed to review socio-demographic and clinical characteristics of bipolar patients taking LAI treatment for maintenance treatment. METHODS: Clinical records of 56 bipolar patients who are on LAI treatment and followed in Mazhar Osman Mood Clinic (MOMC) of Selcuk University Medical Faculty were evaluated. Descriptive statistical analysis was performed with Statistical Package for the Social Sciences (SPSS). RESULTS: Nearly half of the patients were male (n:29, 52%). 49,1% of the patients were married. The mean age was 37.1±12.2 years and the mean duration of education was 11.1±4.2 years. All of the patients were diagnosed with bipolar 1 disorder. Most of the patients (64,7%) was on aripiprazole LAI while remaining was receiving paliperidone LAI for maintenance treatment. We found a significant reduction in the number of manic episodes after long-acting treatment (p<0.001), but we could not find any difference for depression. Ten of the patients discontinued the treatment due to the side effects, extrapyramidal side effects were the most common side effects. Eight of the patients were switched from paliperidone treatment to aripiprazole treatment due to side effects, especially hyperprolactinemia. Relapse was observed in 46,4% of the patients and there was no difference between aripiprazole and paliperidone in terms of relapse rate. CONCLUSIONS: LAI new generation antipsychotics are taking place in long-term treatment of bipolar disorder via improving treatment adherence. Side effect profile of aripiprazole and paliperidone are different. However, we could not find any difference between two drugs in terms of side effects and relapse rates. Small sample size and shorter duration of follow-up should be considered as limitations. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10661534/ http://dx.doi.org/10.1192/j.eurpsy.2023.1457 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Yavuz, E.
Altınbaş, K.
Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
title Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
title_full Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
title_fullStr Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
title_full_unstemmed Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
title_short Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
title_sort long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661534/
http://dx.doi.org/10.1192/j.eurpsy.2023.1457
work_keys_str_mv AT yavuze longactingnewgenerationantipsychoticsinthemaintenancetreatmentofbipolardisorders
AT altınbask longactingnewgenerationantipsychoticsinthemaintenancetreatmentofbipolardisorders